## AMENDMENT

 (Previously presented): A method for inhibiting the growth of tumor cells in an individual comprising administering to the individual a pharmacologically effective dose of a compound having a structural formula

wherein X is oxygen;

Y is oxygen, NH or NCH3;

R<sup>1</sup> is -(CH<sub>2</sub>)<sub>1-3</sub>CO<sub>2</sub>H, -(CH<sub>2</sub>)<sub>7</sub>CO<sub>2</sub>H, -CH<sub>2</sub>CONH<sub>2</sub>, -CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CON(CH<sub>2</sub>CO<sub>2</sub>H)<sub>2</sub>, -(CH<sub>2</sub>)<sub>2</sub>OH, -(CH<sub>2</sub>)<sub>3</sub>NH<sub>3</sub>Cl, or -(CH<sub>2</sub>)<sub>2</sub>OSO<sub>3</sub>NHEt<sub>3</sub>;

R<sup>2</sup> and R<sup>3</sup> are independently hydrogen or R<sup>4</sup>;

R4 is methyl; and

- 2. (Previously presented): The method of claim 1, wherein said compound is  $\alpha$ -tocotrienol,  $\gamma$ -tocotrienol or  $\delta$ -tocotrienol.
- 3. (Original): The method of claim 1, wherein said compound is 2,5,7,8-tetramethyl-2R-(4,8,12-trimethyl-3,7.11 E:Z tridecatrien) chroman-6-yloxy) acetic acid.

- 4. (Previously presented): The method of claim 1, wherein said compound induces apoptosis, DNA synthesis arrest, cell cycle arrest, or cellular differentiation in cells comprising said tumor.
- (Previously presented): The method of claim 1, wherein said compound is administered in a dose of about 1 mg/kg to about 60 mg/kg.
- (Previously presented): The method of claim 5, wherein administration of said composition is oral, topical, liposomal/aerosol, intraocular, intranasal, parenteral, intravenous, intramuscular, or subcutaneous.
- 7. (Canceled).
- 8. (Previously presented): The method of claim 1, wherein said tumor cells comprise an ovarian cancer, a cervical cancer, an endometrial cancer, a bladder cancer, a lung cancer, a breast cancer, a testicular cancer, a prostate cancer, a glioma, a fibrosarcoma, a retinoblastoma, a melanoma, a soft tissue sarcoma, an osteosarcoma, a leukemia, a colon cancer, a carcinoma of the kidney, a pancreatic cancer, a basel cell carcinoma, or a squamous cell carcinoma.
- 9-13. (Canceled).
- 14. (Previously presented): A method of inducing apoptosis of a cell, comprising the step of contacting said cell with a pharmacologically effective dose of a compound having a structural formula

wherein X is oxygen:

Y is oxygen, NH or NCH3;

 $R^1$  is -(CH<sub>2</sub>)<sub>1-5</sub>CO<sub>2</sub>H, -(CH<sub>2</sub>)<sub>7</sub>CO<sub>2</sub>H, -CH<sub>2</sub>CONH<sub>2</sub>, -CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CON(CH<sub>2</sub>CO<sub>2</sub>H)<sub>2</sub>, -(CH<sub>2</sub>)<sub>2</sub>OH, -(CH<sub>2</sub>)<sub>3</sub>NH<sub>3</sub>Cl or -(CH<sub>2</sub>)<sub>2</sub>OSO<sub>3</sub>NHE<sub>5</sub>;

R<sup>2</sup> and R<sup>3</sup> are independently hydrogen or R<sup>4</sup>;

R4 is methyl: and

- 15. (Previously presented): The method of claim 14, wherein said compound is  $\alpha$ -tocotrienol,  $\gamma$ -tocotrienol or  $\delta$ -tocotrienol.
- (Original): The method of claim 14, wherein said compound is 2,5,7,8-tetramethyl-2R-(4,8,12-trimethyl-3,7,11 E:Z tridecatrien) chroman-6-yloxy) acetic acid.
- 17. (Canceled).
- 18. (Previously presented): The method of claim 1, wherein R<sup>1</sup> is -(CH<sub>2</sub>)<sub>1-5</sub>CO<sub>2</sub> or -CH<sub>2</sub>)<sub>7</sub>CO<sub>2</sub>H.
- 19. (Previously presented): The method of claim 1, wherein R<sup>1</sup> is -CH<sub>2</sub>CONH<sub>2</sub>.
- 20. (Previously presented): The method of claim 1, wherein R1 is -CH2CO2CH3.
- 21. (Previously presented): The method of claim 1, wherein R<sup>1</sup> is -CH<sub>2</sub>CON(CH<sub>2</sub>CO<sub>2</sub>H)<sub>2</sub>.
- 22. (Previously presented): The method of claim 1, wherein R<sup>1</sup> is -(CH<sub>2</sub>)<sub>2</sub>OH.
- 23. (Previously presented): The method of claim 1, wherein R<sup>1</sup> is -(CH<sub>2</sub>)<sub>3</sub>NH<sub>3</sub>Cl.
- 24. (Previously presented): The method of claim 1, wherein R<sup>1</sup> is -(CH<sub>2</sub>)<sub>2</sub>OSO<sub>3</sub>NHEt<sub>3</sub>.
- 25-33. (Canceled)

- 34. (Previously presented): The method of claim 1, wherein R<sup>2</sup> is hydrogen.
- 35. (Previously presented): The method of claim 1, wherein R<sup>2</sup> is methyl.
- 36. (Previously presented): The method of claim 1, wherein R<sup>3</sup> is hydrogen.
- 37. (Previously presented): The method of claim 1, wherein R<sup>3</sup> is methyl.
- 38. (Previously presented): The method of claim 1, wherein R<sup>4</sup> is methyl.
- 39. (Canceled)
- 40. (Previously presented): The method of claim 1, wherein Y is NCH3.
- 41. (Previously presented): The method of claim 1, wherein Y is NH.
- 42. (Previously presented): The method of claim 14, wherein  $R^1$  is -(CH2)1-3CO2 or -(CH2)7CO2H.
- 43. (Previously presented): The method of claim 14, wherein R<sup>1</sup> is -CH<sub>2</sub>CONH<sub>2</sub>
- 44. (Previously presented): The method of claim 14, wherein R<sup>1</sup> is -CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>.
- 45. (Previously presented): The method of claim 14, wherein R<sup>1</sup> is -CH<sub>2</sub>CON(CH<sub>2</sub>CO<sub>2</sub>H)<sub>2</sub>.
- 46. (Previously presented): The method of claim 14, wherein R<sup>1</sup> is -(CH<sub>2</sub>)<sub>2</sub>OH.
- 47. (Previously presented): The method of claim 14, wherein R<sup>1</sup> is -(CH<sub>2</sub>)<sub>3</sub>NH<sub>3</sub>Cl.
- 48. (Previously presented): The method of claim 14, wherein R<sup>1</sup> is -(CH<sub>2</sub>)<sub>2</sub>OSO<sub>3</sub>NHEt<sub>3</sub>.
- 49-57. (Canceled)
- 58. (Previously presented): The method of claim 14, wherein R<sup>2</sup> is hydrogen.
- 59. (Previously presented): The method of claim 14, wherein R<sup>2</sup> is methyl.
- 60. (Previously presented): The method of claim 14, wherein R3 is hydrogen.

- 61. (Previously presented): The method of claim 14, wherein R<sup>3</sup> is methyl.
- 62. (Previously presented): The method of claim 14, wherein R<sup>4</sup> is methyl.
- 63. (Canceled)
- 64. (Previously presented): The method of claim 14, wherein Y is NCH<sub>3</sub>.
- 65. (Previously presented): The method of claim 14, wherein Y is NH.
- 66. (Previously presented): The method of claim 1, wherein the compound has the structural formula

wherein X is oxygen;

Y is oxygen, NH or NCH3;

 $R^{1} \text{ is -(CH}_{2})_{1\text{-}3}CO_{2}H, \text{-CH}_{2}CON(CH_{2}CO_{2}H)_{2}, \text{-(CH}_{2})_{3}NH_{3}Cl, \text{ or -(CH}_{2})_{2}OSO_{3}NHEt_{3}; \\$ 

R2 and R3 are independently hydrogen or R4;

R4 is methyl; and

67. (Previously presented): The method of claim 14, wherein the compound has the structural formula

wherein X is oxygen;

Y is oxygen, NH or NCH3;

 $R^1 \text{ is -(CH_2)_{1-3}CO}_2H, \text{-CH}_2CON(CH_2CO}_2H)_2, \text{-(CH}_2)_3NH_3CI, \text{ or -(CH}_2)_2OSO_3NHEt_3;}$ 

R<sup>2</sup> and R<sup>3</sup> are independently hydrogen or R<sup>4</sup>;

R4 is methyl; and